CDKN2A and mesothelioma: Another tested drug in our screen, Palbociclib, PD0332991, a CDK4/CDK6 inhibitor, that is supposed to target the most frequent deletion in mesothelioma, CDKN2A, showed only minor effects in our cell lines (Table 2).